Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present)
Molecules · 26.02.2026 · 31 (5) · 779
DOI: 10.3390/molecules31050779 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 26.02.2026. Verfasst von Jyoti Dnyaneshwar Palkhede und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gachon Institute of Pharmaceutical Sciences and College of Pharmacy, Gachon University, Hambakmoe-ro 191, Yeonsu-gu, Incheon 21936, Republic of Korea. Hauptthemen laut MEDLINE: Hydantoins, Drug Discovery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Ministry of Science and ICT, Gachon University research fund.
Abstract (Originalsprache)
Hydantoins, exemplified by the imidazolidine-2,4-dione core, are privileged scaffolds in medicinal chemistry due to their compact structure, versatile hydrogen-bonding capacity, ability to fine-tune physicochemical properties for drug-like molecules, and potential to engage a diverse array of biological targets. This review highlights major advances in hydantoin-based drug discovery since 2019, emphasizing their evolving applications in oncology; neurology; infectious diseases; and cardiovascular, metabolic, and immune disorders. Recent studies demonstrate their success as kinase inhibitors, androgen receptor antagonists, and metalloprotease inhibitors, and emerging roles in modulating sterol isomerase, glycogen synthase kinase-3β, and ADAMTS family enzymes. Novel hybrid scaffolds—such as catechol–hydantoins, β-carboline–hydantoins, and spirocyclic thiohydantoins—have yielded potent and selective anticancer and antiviral leads. The discovery of BAY-9835 and GLPG1972 underscores the clinical potential of hydantoin-based metalloproteinase inhibitors in cardiovascular and osteoarthritic conditions. Furthermore, new antimicrobial, antimalarial, and antileishmanial derivatives illustrate the scaffold’s capacity to address multidrug resistance and neglected tropical diseases. Advances in computational design, stereochemical optimization, and hybridization strategies have expanded the structural and functional diversity of hydantoins, enhancing their target selectivity and pharmacokinetic profiles. Overall, hydantoins and their analogs remain at the forefront of small-molecule drug discovery, offering rich prospects for therapeutic innovation in diverse disease areas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gachon Institute of Pharmaceutical Sciences and College of Pharmacy, Gachon University, Hambakmoe-ro 191, Yeonsu-gu, Incheon 21936, Republic of Korea.
ORCID-Profile: Jyoti Dnyaneshwar Palkhede
Förderung
- Ministry of Education
- Ministry of Science and ICT
- Gachon University research fund
- National Research Foundation of Korea
- Gachon University research fund of 2020
Zitieren
APA
Palkhede, J. D., Park, E. J., Darlami, O., & Shin, D. (2026). Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present). Molecules, 31(5), 779. https://doi.org/10.3390/molecules31050779
Vancouver
Palkhede JD, Park EJ, Darlami O, Shin D. Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present). Molecules. 2026;31(5):779. doi:10.3390/molecules31050779
BibTeX
@article{Palkhede2026,
author = {Palkhede, Jyoti Dnyaneshwar and Park, Eo-Jin and Darlami, Om and Shin, Dongyun},
title = {Recent Applications of Hydantoins in Drug Discovery: Updates (2019~Present)},
journal = {Molecules},
year = {2026},
volume = {31},
number = {5},
pages = {779},
doi = {10.3390/molecules31050779}
}
EUVIMED